ERBB2 and breast carcinoma: Recently, Agostinetto et al. evaluated the transcriptomic profile of the HER2-low group using the PAM50 intrinsic subtype classification and data on 804 primary breast cancers (n = 410 HER2 1+/2+ tumors, among which 74 were TNBC) from the TCGA dataset [12].